home > drugs a-z list > emend injection (fosaprepitant dimeglumine injection) drug center > emend injection (fosaprepitant dimeglumine injection) drug - medication guide and patient information

EMEND®
(EE mend)
(fosaprepitant dimeglumine) for Injection

Read this Patient Information before you start receiving EMEND (fosaprepitant dimeglumine injection) for Injection and each time you are scheduled to receive EMEND (fosaprepitant dimeglumine injection) for Injection. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.

What is EMEND (fosaprepitant dimeglumine injection) for Injection?

EMEND (fosaprepitant dimeglumine injection) for Injection is a prescription medicine used in adults to prevent nausea and vomiting caused by certain anti-cancer (chemotherapy) medicines. EMEND (fosaprepitant dimeglumine injection) for Injection is always used with other medicines that treat nausea and vomiting.

EMEND (fosaprepitant dimeglumine injection) for Injection is not used to treat nausea and vomiting that you already have.

EMEND (fosaprepitant dimeglumine injection) for Injection should not be used continuously for a long time (chronic use).

It is not known if EMEND (fosaprepitant dimeglumine injection) for Injection is safe and effective in children.

Who should not take EMEND (fosaprepitant dimeglumine injection) for Injection?

Do not take EMEND (fosaprepitant dimeglumine injection) for Injection if you:

• are taking any of the following medicines:
  • pimozide (ORAP® )
  • cisapride (PROPULSID® )

Taking EMEND (fosaprepitant dimeglumine injection) for Injection with any of these medicines could cause serious or life-threatening problems.

• are allergic to any of the ingredients in EMEND (fosaprepitant dimeglumine injection) for Injection. See the end of this leaflet for a list of all the ingredients in EMEND (fosaprepitant dimeglumine injection) for Injection.

What should I tell my doctor before receiving EMEND (fosaprepitant dimeglumine injection) for Injection?

Before you receive EMEND (fosaprepitant dimeglumine injection) for Injection, tell your doctor if you:

• have liver problems.
• are pregnant or plan to become pregnant. It is not known if EMEND (fosaprepitant dimeglumine injection) for Injection can harm your unborn baby.
  Women who use birth control medicines containing hormones to prevent pregnancy (birth control pills, skin patches, implants, and certain IUDs) should also use a backup method of birth control during treatment with EMEND (fosaprepitant dimeglumine injection) for Injection and for up to 1 month after using EMEND (fosaprepitant dimeglumine injection) for Injection to prevent pregnancy.
• are breastfeeding or plan to breastfeed. It is not known if EMEND (fosaprepitant dimeglumine injection) for Injection passes into your milk and if it can harm your baby. You and your doctor should decide if you will take EMEND (fosaprepitant dimeglumine injection) for Injection or breastfeed. You should not do both.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

EMEND (fosaprepitant dimeglumine injection) for Injection may cause serious life-threatening reactions if used with certain medicines. See the section “Who should not take EMEND (fosaprepitant dimeglumine injection) for Injection?”.

EMEND (fosaprepitant dimeglumine injection) for Injection may affect how other medicines work, and other medicines may affect how EMEND (fosaprepitant dimeglumine injection) for Injection works. Ask your doctor or pharmacist before you take any new medicine. They can tell you if it is safe to take the medicine with EMEND (fosaprepitant dimeglumine injection) for Injection.

Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.

How will I receive EMEND (fosaprepitant dimeglumine injection) for Injection?

You will receive EMEND (fosaprepitant dimeglumine injection) for Injection in one of two ways:

1. EMEND (fosaprepitant dimeglumine injection) for Injection 150 mg given on Day 1 only.

• Day 1 (Day of chemotherapy): EMEND (fosaprepitant dimeglumine injection) for Injection 150 mg will be given to you by infusion in your vein (intravenous) about 30 minutes before you start your chemotherapy treatment.

Or

2. EMEND (fosaprepitant dimeglumine injection) for Injection 115 mg given along with capsules of EMEND (fosaprepitant dimeglumine injection) .

• Day 1 (Day of chemotherapy): EMEND (fosaprepitant dimeglumine injection) for Injection 115 mg will be given to you by infusion in your vein (intravenous) about 30 minutes before you start your chemotherapy treatment.
• You will get a prescription for two capsules of EMEND (fosaprepitant dimeglumine injection) .
• Day 2 and Day 3 (the two days after chemotherapy): Take one 80-mg capsule of EMEND (fosaprepitant dimeglumine injection) (white) by mouth, each morning for the 2 days after your chemotherapy treatment.
• If you take the blood thinner medicine warfarin sodium (COUMADIN®, JANTOVEN®), your doctor may do blood tests after you take EMEND (fosaprepitant dimeglumine injection) to check your blood clotting.

What are the possible side effects of EMEND (fosaprepitant dimeglumine injection) for Injection?

EMEND (fosaprepitant dimeglumine injection) for Injection may cause serious side effects, including:

• Serious allergic reactions. Allergic reactions can happen suddenly with EMEND (fosaprepitant dimeglumine injection) for Injection and may be serious. Tell your doctor or nurse right away if you have flushing or redness of your face or skin, or trouble breathing during or soon after you receive EMEND (fosaprepitant dimeglumine injection) for Injection.
  EMEND (fosaprepitant dimeglumine injection) capsules can also cause allergic reactions. If you receive EMEND (fosaprepitant dimeglumine injection) for Injection on Day 1, and then take EMEND (fosaprepitant dimeglumine injection) capsules on Days 2 and 3, stop taking the EMEND (fosaprepitant dimeglumine injection) capsules and call your doctor right away if you have any of these signs or symptoms of an allergic reaction:
• hives
• rash
• itching
• redness of the face or skin
• trouble breathing or swallowing.

The most common side effects of EMEND (fosaprepitant dimeglumine injection) for Injection include:

• hiccups
• weakness or tiredness
• changes in liver function blood test results. Your doctor will check you for this.
• headache
• constipation
• loss of appetite
• indigestion
• diarrhea
• belching

Infusion-site side effects with EMEND (fosaprepitant dimeglumine injection) for Injection may include pain, hardening, redness or itching at the site of infusion. Swelling (inflammation) of a vein caused by a blood clot can also happen at the infusion site. Tell your doctor if you get any infusion-site side effects.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of EMEND (fosaprepitant dimeglumine injection) for Injection. For more information ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA1088.

General information about EMEND (fosaprepitant dimeglumine injection) for Injection

This Patient Information leaflet summarizes the most important information about EMEND (fosaprepitant dimeglumine injection) for Injection. If you would like to know more information, talk with your doctor. You can ask your doctor or pharmacist for information about EMEND (fosaprepitant dimeglumine injection) for Injection that is written for health professionals. For more information about EMEND (fosaprepitant dimeglumine injection) for Injection call 1-800-622-4477 or go to www.emend (fosaprepitant dimeglumine injection) .com.

What are the ingredients in EMEND for Injection?

Active ingredient: fosaprepitant dimeglumine

Inactive ingredients: edetate disodium, polysorbate 80, lactose anhydrous, sodium hydroxide and/or hydrochloric acid (for pH adjustment).

Last reviewed on RxList: 12/15/2010
This monograph has been modified to include the generic and brand name in many instances.